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"CORRESPONDENT LINK" BETWEEN A PROTEIN AND
NUCLEIC ACID SEQUENCE DOES NOT RENDER THE
GENE OBVIOUS
In Re Bell, 991 F.2d 781 (Fed. Cir. 1993)
Kamrin T. MacKnightt
On 20 April 1993, the United States Court of Appeals for the
Federal Circuit reversed a decision by the Board of Patent Appeals
& Interferences (Board), and granted a patent directed to genes
which code for insulin-like human hormones to Chiron Corporation
(Emeryville, CA).1
The decision written by Judge Lourie,2 overturned the Exam-
iner's final rejection of Bell's patent application Serial No. 065,673,
entitled "Preproinsulin-like Growth Factors I and II," on the
ground of obviousness under 35 U.S.C. § 103. The Federal Circuit
ruled that the "Board erred in concluding that the claimed nucleic
acid molecules would have been obvious in light of the cited prior
art."
'3
BACKGROUND
The claims of the application in dispute are directed to nucleic
acids (DNA and RNA)4 which encode human insulin-like growth
Copyright © 1993 by Kamrin T. MacKnight.
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1. In re Bell, 991 F.2d 781 (Fed. Cir. 1993). The application was filed in the names of
three inventors, Graeme I. Bell, Leslie B. Rall and James P. Merryweather. Hereinafter, the
patent application and its components are referred to as "Bell." Chiron Corp. is the assignee.
2. The case was heard before Judges Rich, Lourie, and Schall.
3. Bell, 991 F.2d at 782.
4. The two major types of nucleic acid are deoxyribonucleic acid (DNA) and
ribonucleic acid (RNA). DNA is the "genetic blueprint" for the vast majority of organisms
(including humans). DNA is a double helix, similar in shape to a spiral staircase. The four
"bases"-adenine, thymine, guanine, and cytosine form the steps of the staircase; sugar and
phosphate molecules comprise the handrails. RNA is similar to DNA in that it contains
adenine, guanine, and cytosine. However, it contains uracil, rather than thymine. For a
description of basic genetics and recombinant DNA technology, the reader is referred to such
texts as BENJAMIN LEWIN, GENES (2d ed. 1985); BRUCE ALBERTS ET AL., MOLECULAR
BIOLOGY OF THE CELL (1983); MAXINE SINGER AND PAUL BERG, GENES AND GENOMES
(1991). In re O'Farrell, 853 F.2d 894, 895-899 (Fed. Cir. 1988), also contains a general dis-
cussion of the technology involved here.
COMPUTER & HIGH TECHNOLOGY LAWJOURNAL
factors I and II (IGF). s Claim 25 (conceded by the parties to be
representative of the claims at issue) includes the following:
A composition comprising nucleic acid molecules containing a
human sequence encoding insulin-like growth factor (hIGF) sub-
stantially free of nucleic acid molecules not containing said
(hIGF) sequence, wherein said hIGF sequence is selected from
the group consisting of (a) . . . ; (b) . .. ; (c) nucleic acid se-
quences complementary to (a) or (b); and (d) fragments of (a),
(b), or (c) that are at least 18 bases in length and which will
selectively hybridize to human genomic DNA encoding hIGF.6
The relevant prior art consisted of two publications which dis-
close the amino acid sequences7 of IGF I and II,8 and U.S. Patent
No. 4,394,443 issued to Weissman et al., entitled "Method for Clon-
ing Genes." The Weissman patent describes a general method for
the isolating genes for which at least a short amino acid sequence is
known.9 This method involves preparation of a nucleic acid probe 0
which corresponds to the known amino acid sequence and using
this probe to isolate the gene of interest. Weissman teaches that it is
advantageous to design and use a probe which is based on amino
acids specified by unique codons.11
The Examiner rejected Bell's claims as obvious over the com-
bined teachings of Rinderknecht and Weissman, after determining
that it would have been obvious, "albeit tedious," to prepare probes
according to Weissman, based on the Rinderknecht amino acid se-
quences." The Examiner argued that an ordinary artisan would
know how to determine the nucleic acid sequence which corre-
sponds to a known amino acid sequence. 3 Based on this argument,
5. These growth factors are single-chain serum proteins involved in the mediation of
cell growth following the administration of growth hormones.
6. Bell, 991 F.2d at 782, n.3. The text omitted here discloses the nucleic acid
sequences.
7. Amino acids are the "building blocks" of proteins.
8. Rinderknecht et al., The Amino Acid Sequence of Human Insulin-Like Growth Fac-
tor I and Its Structural Homology with Proinsulin, 253 J. BIOL. CHEM., 2769-76 (1978); and
Rinderknecht et al., Primary Structure of Human Insulin-like Growth Factor II, 89 FEBS
LETrER, 283-86 (May 1978).
9. Specifically, Weissman describes the isolation of a gene which encodes a human
histocompatibility antigen, a protein unrelated to IGF.
10. A probe is a sequence of DNA or RNA which is used to identify a particular se-
quence of interest in DNA or RNA of unknown sequence.
11. A "codon" is a sequence of three nucleotides which codes for one of the twenty
natural amino acids. Because there are twenty animo acids and sixty-four possible codons,
most amino acids are coded for by more than one codon.
12. See Bell, 991 F.2d at 783.
13. Id.
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the Examiner rejected the application because the claimed se-
quences and hosts1 4 would have been readily determinable by and
obvious to, those of ordinary skill in the art at the time the inven-
tion was made. 5
The Board upheld the Examiner's rejection of Bell's claims, by
holding that the Examiner had established a prima facie case of ob-
viousness for the claimed sequences, despite ,the lack of conven-
tional indicia of obviousness. 6 The Board's rationale was that
although a protein and the DNA encoding it are not structurally
similar, they are linked based on the DNA code. In view of Weiss-
man, the Board determined that there was no evidence "that one
skilled in the art, knowing the amino acid sequences of the desired
proteins, would not have been able to predictably clone the desired
DNA sequences without undue experimentation."' 7
Bell argued that the Patent and Trademark Office (PTO) failed
to establish its prima facie case of obviousness, because it did not
show how the prior art references, alone or in combination, taught
or suggested their invention. Importantly for Bell, these arguments
are in agreement with previous decisions which have held that the
PTO bears the burden of establishing a prima facie case of obvi-
ousness. 8 Thus, despite the Board's support of the Examiner's re-
jection, the Court agreed with Bell.
DISCUSSION
The Federal Circuit reviews the Board's rejection of patent ap-
plications based on obviousness grounds de novo.' 9 As previously
stated, "[a] prima facie case of obviousness is established when the
teachings from the prior art itself would appear to have suggested
the claimed subject matter to a person of ordinary skill in the art."20
The Court indicated that the Examiner's rationale that a "cor-
respondent link" between a gene and its protein via the genetic code
renders the gene obvious if the amino acid sequence is known,2 '
amounts to a rejection based on the two Rinderknecht publications
14. The "hosts" are the cells used to prepare the probes.
15. Bell, 991 F.2d at 783.
16. Id. This rejection was based on structural similarity between the DNA encoding
for IGF-I and the amino acid sequence of the IGF-I polypeptide.
17. Id.
18. In re Fine, 837 F.2d 1071, 1074 (Fed. Cir. 1988).
19. In re Vaeck, 947 F.2d 488, 493 (Fed. Cir. 1991).
20. In re Rinehart, 531 F.2d 1048, 1151 (CCPA 1976).
21. Bell, 991 F.2d at 783.
1993]
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alone.22
The Court realized that unlike chemical homologs, analogs
and isomers, which may create a prima facie case of obviousness,23
the established relationship between a gene and its correspondent
protein does not make a gene prima facie obvious over its corre-
spondent protein.24 The Court recognized that while the knowl-
edge of the protein structure and sequence may be used to
hypothesize about the gene sequence, the degeneracy of the genetic
code results in a vast number of potential nucleotide sequences
which might code for a specific protein.25
However, the Court also stressed that when the amino acid se-
quence is known to be specified exclusively by unique codons, the
gene may be rendered obvious.26 In this case, Bell argued, without
contradiction, that the Rinderknecht amino acids could be coded
for by more than 1036 different nucleotide sequences, only a few of
which are the human sequences claimed in the patent application. 7
The Court found that the nearly infinite number of possibilities sug-
gested by the prior art, and the failure of the cited prior art to sug-
gest which of these possibilities were the human sequences claimed,
rendered Bell's sequences non-obvious.28 Thus, because there was
nothing in the prior art to suggest which of the 1036 Rinderknecht
sequences correspond to the IGF gene, the Court found that the
PTO did not meet its burden of establishing that the prior art would
have suggested the claimed sequences.29 The Court stressed that
Bell did not claim all possible 1036 nucleic acids which potentially
-code for IGF, nor did he claim all nucleic acids coding for a protein
with the biological activity of IGF. 0
22. Id.
23. See In re Dillon, 919 F.2d 688, 696 (Fed. Cir. 1990)(en banc), cert. denied, 111 S.
Ct. 1682 (1991).
24. Bell, 991 F.2d at 784.
25. This degeneracy is based on the fact that there are sixty four possible codons, but
only twenty natural amino acids. In addition to "degeneracy" in the genetic code, the ten-
dency for similar amino acids to be represented by related codons is believed to minimize the
effects of mutations. This helps to ensure that a single random base change has an increased
probability (as compared with a completely random assignment of codons) of resulting in
either no amino acid substitution or substitution by an amino acid of similar character.
Lewin, supra note 4, at 96.
26. Bell, 991 F.2d at 784. In footnote 6, the Court indicated that it "express[ed] no
opinion concerning the reverse proposition, that knowledge of the structure of a DNA, e.g., a
cDNA, might make a coded protein obvious." Id. Thus, the Court has left this avenue open
for continuing debate.
27. Bell, 991 F.2d at 784.
28. Id.
29. Id.
30. Id.
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The Court also reviewed obviousness determinations based on
combinations of references. It reiterated the requirement that obvi-
ousness "cannot be established by combining the teachings of the
prior art to produce the claimed invention, absent some teaching or
suggestion supporting the combination."31 The Court also repeated
the rule that the teachings of a reference and the determination of
whether it teaches toward or away from the claimed invention are
questions of fact.32
The Weissman patent suggests that it is generally advantageous
to design probes based on amino acid sequences specified by unique
codons. 33 The PTO argued that this suggestion would be "easily"
applied to the isolation of genes for an array of proteins, including
peptide hormones. The PTO further argued that, in view of Weiss-
man, a gene is rendered obvious once the amino acid sequence of
the corresponding protein is known. However, the Court refused to
view Weissman in such a broad scope. The Court indicated that
Weissman teaches away from the present invention because it is
directed toward situations in which unique codons are known. In
contrast, the present invention involves no unique codons (or only
one).34
While reaffirming that "a reference must be considered not
only for what it expressly teaches, but also for what it fairly sug-
gests,"' 35 the Court found that because Weissman does not suggest
how to apply its teachings to amino acids sequences lacking unique
codons, it could not say Weissman "fairly teaches" that its methods
should be combined with the teachings of Rinderknecht.36
The Court also discussed the emphasis the PTO placed on the
similarities in the methods used by Bell and Weissman to produce
their respective isolated genes. As Bell claims compositions of mat-
ter, rather than a method, the PTO's focus was found to be mis-
placed. This is due to settled law that for composition of matter
claims, the issue is the obviousness of claimed compositions, not the
31. ACS Hosp. Sys. v. Montefiore Hosp., 732 F.2d 1572, 1577 (Fed. Cir. 1984).
32. See Raytheon Co. v. Roper Corp., 724 F.2d 951, 960-1 (Fed. Cir. 1983), cert. de-
nied, 469 U.S. 835 (1984).
33. Bell, 991 F.2d at 784.
34. In contrast to the Weissman sequences, Bell used a probe with 23 nucleotides based
on a sequence of eight amino acids, none of which were unique. Rinderknecht indicates that
IGF-I has only a single amino acid coded with a unique codon and IGF-II has none. Thus,
Weissman is in opposition to Bell.
35. In re Burckel, 592 F.2d 1175, 1179 (CCPA 1979).
36. Bell, 991 F.2d at 785.
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obviousness of the method by which the composition is made.37
CONCLUSION
The Court concluded that: (1) the Board was clearly in error in
its determination that Weissman teaches toward, rather than away
from Bell's claimed sequences; (2) the requisite teaching or sugges-
tion to combine the prior art references was absent; and (3) the PTO
did not establish that the claimed sequences would have been obvi-
ous over the combination of Weissman and Rinderknecht. 38 The
Court's conclusion that the combination of prior art references does
not render the claimed invention obvious, resulted in reversal of the
Board's decision to affirm the Examiner's rejection of Bell's Claims
25-46.
The importance of Bell is that it is in opposition to the PTO's
policy to declare as gene derived from known amino acid sequences
by use of general cloning methods to be obvious. 39 This decision
will require Examiners to take a closer look at this type of patent
application on an individual basis in order to make a decision re-
garding obviousness.
The Bell decision is an addition to a growing body of case law
dedicated to the unique concerns related to biotechnology. 40 This
case law should provide encouragement for biotechnology compa-
nies desiring to protect their inventions which are the products of
expensive, labor and time-intensive research. This law provides at-
tractive incentives (i.e., patent protection) to companies who devote
their resources to research. It is an indication that the current
boom in biotechnology will continue long into the future.
37. In re Thorpe, 777 F.2d 695 (Fed. Cir. 1985). "Patentability of a product does not
depend upon its method of production." Id., at 697.
38. Bell, 991 F.2d at 785.
39. See Rex Bossert, Ruling Hailed as Protection for the Future, DAILY JOURNAL, April
26, 1993, at 1.
40. For example, this decision is consistent with other recent Federal Circuit cases, in
which the Court granted patents for genetic materials used in treatment of anemia and multi-
ple sclerosis.
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